- Why in news
- On 21 September 2026, MoS Health Anupriya Patel launched the 7th National Formulary of India at the 6th National Pharmacovigilance Week and announced that the government has approved a Biovigilance Programme of India, led by the Indian Pharmacopoeia Commission.
- What it is
- The Indian Pharmacopoeia Commission (IPC) is an autonomous body under the Union Health Ministry. It sets drug quality standards through the Indian Pharmacopoeia. It also hosts the National Coordination Centre of the Pharmacovigilance Programme of India (PvPI), which collects and analyses adverse drug reaction reports.
- Biovigilance Programme
- Approved by the Government of India. IPC will lead reporting, assessment, monitoring and prevention of adverse events linked to medicines and biological products used in organ and tissue transplantation, for donors and recipients.
- Three vigilance programmes
- Pharmacovigilance covers medicines, materiovigilance covers medical devices, and biovigilance covers transplant procedures. Together they form the safety-monitoring net.
- PvPI coordination
- PvPI is coordinated by the National Coordination Centre at IPC. It collects, assesses and analyses adverse drug reaction information.
- ADR reporting centres
- About 1,150 centres operate in public and private hospitals and medical colleges. The government plans to extend them to primary healthcare level.
- IPC and global harmonisation
- IPC became a member of the Pharmacopoeial Discussion Group in 2023. Around 25 countries recognise the Indian Pharmacopoeia.
Don’t confuse with Pharmacovigilance vs materiovigilance vs biovigilance: Pharmacovigilance tracks adverse drug reactions (PvPI). Materiovigilance tracks adverse events from medical devices (MvPI). Biovigilance tracks adverse events in organ and tissue transplantation.
Don’t confuse with National Formulary of India vs Indian Pharmacopoeia: The Indian Pharmacopoeia sets quality standards for drugs. The NFI is a guide for prescribing and rational use of medicines. IPC publishes both.
Laws, judgments and statutory bodies: 30 Prelims questions since 2013 (what the law says, who chairs, legal basis). In Mains, 44 news-triggered questions, most in GS2, asking for provisions and challenges.
Why it matters
- Extends safety monitoring from drugs and devices to transplants, closing a gap in patient safety.
- A domestic evidence base on drug safety supports self-reliance in healthcare and India's role in global regulation.
Problems
- Under-reporting, especially by patients, which the Minister called the 'missing link'.
- Reporting capacity is mostly in hospitals and medical colleges, with little at primary healthcare level.
Way forward
- Extend ADR reporting centres to primary healthcare and encourage patient reporting through apps and helplines.
- Use AI and data analytics to detect safety signals quickly.
Put in your answer
India's WHO database ranking: India moved from 123rd position in 2009–2014 to 8th globally in contributions to the WHO patient safety database, as stated by the Minister.
ADR network size: About 1,150 ADR reporting centres show the scale of the existing network.
- 2014Mains GS3 · Q11Overuse of antibiotics causing drug resistance; monitoring and control mechanisms.
- 2013Mains GS3 · Q14Define Fixed Dose Drug Combinations; discuss their merits and demerits.
UPSC’s own questions that come close to this issue, from our Prelims and Mains banks.
No practice question for this one; the card may still help an answer. Why: Lasting health-regulation topic under the Indian Pharmacopoeia Commission. Facts are thin for a statement-based question, and no debate for Mains.
Worth revising until Prelims 2028: most news questions come within two years of the event.